After a comprehensive two-year follow-up, researchers found that MRI-guided stereotactic body radiotherapy (SBRT) for prostate cancer significantly reduced long-term side effects and improved quality ...

We remain on track for phase 2b and phase 3 topline data in non-metastatic, localized prostate cancer for CAN-2409 in the fourth quarter ...

LOUISVILLE, Ky. -- More than half of patients with newly diagnosed metastatic kidney cancer responded to a novel drug ...

Investigators conducted a trial of MRI as a screening tool to reduce overdetection of insignificant prostate cancer.

Overtreatment of prostate cancer is increasing in the United States among men with limited life expectancy, a new s ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...

Medically reviewed by Amelia MacIntyre, DO Approximately 1 in 8 people with a prostate are diagnosed with prostate cancer ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, ...

Metastatic castration-resistant prostate cancer (mCRPC) is a severe form of late-stage disease where the tumor can no longer ...

A recent study led by Cedars-Sinai researchers reveals that a growing number of older men in the U.S. with intermediate or ...

The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically changed in recent years. However, aside from drug or hormonal therapies, other ...

“The MMAI risk classifier is a more precise and accurate prognosticator of metastasis than NCCN risk groups,” Dr Tward’s team wrote. “This approach aims to prevent both overtreatment and ...